KBG syndrome patient due to 16q24.3 microdeletion presenting with a paratesticular rhabdoid tumor: Coincidence or cancer predisposition?. Issue 6 (25th April 2018)

• Record Type: Journal Article
• Authors: Behnert, Astrid; Auber, Bernd; Steinemann, Doris; Frühwald, Michael C.; Huisinga, Carolin; Hussein, Kais; Kratz, Christian; Ripperger, Tim
• Is Part Of: American journal of medical genetics. Volume 176:Issue 6(2018)
• Page Start: 1449
• Page End: 1454
• Publication Date: 2018-04-25
• Subjects: 16q24.3 microdeletion -- ANKRD11 -- cancer predisposition -- KBG syndrome -- tumor suppressor gene; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.38724
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract : KBG syndrome is a rare autosomal dominant disorder caused by constitutive haploinsufficiency of the ankyrin repeat domain‐containing protein 11 ( ANKRD11 ) being the result of either loss‐of‐function gene variants or 16q24.3 microdeletions. The syndrome is characterized by a variable clinical phenotype comprising a distinct facial gestalt and variable neurological involvement. ANKRD11 is frequently affected by loss of heterozygosity in cancer. It influences the ligand‐dependent transcriptional activation of nuclear receptors and tumor suppressive function of tumor protein TP53. ANKRD11 thus serves as a candidate tumor suppressor gene and it has been speculated that its haploinsufficiency may lead to an increased cancer risk in KBG syndrome patients. While no systematic data are available, we report here on the second KBG syndrome patient who developed a malignancy. At 17 years of age, the patient was diagnosed with a left‐sided paratesticular extrarenal malignant rhabdoid tumor. Genetic investigations identified a somatic truncating gene variant in SMARCB1, which was not present in the germline, and a constitutional de novo 16q24.3 microdeletion leading to a loss of the entire ANKRD11 locus. Thus, KBG syndrome was diagnosed, which was in line with the clinical phenotype of the patient. At present, no specific measures for cancer surveillance can be recommended for KBG syndrome patients. However, a systematic follow‐up and inclusion of KBG syndrome patients in registries (e.g., those currently established for cancer prone syndromes) will provide empiric data to support or deny an increased cancer risk in KBG syndrome in the future.